AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15450833 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (50 mg preoperatively)
Number of subjects: 120
Study 15450833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 11504983 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of PCP prophylaxis
Number of subjects: 273
Study 9682809 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepines
Number of subjects: 0
Study 9682809 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 8288661 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ultrasound device
Number of subjects: 67
Study 8288661 — intervention group
Group type: COMPARATOR
Intervention: Placebo control device
Number of subjects: 67
Study 2721343 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucometer M Diabetes Management System (experimental group)
Number of subjects: 57
Study 2721343 — intervention group
Group type: COMPARATOR
Intervention: Meters without memory (control group)
Number of subjects: 57
Study 2721343 — intervention group
Group type: COMPARATOR
Intervention: Both groups (experimental and control)
Number of subjects: 57
Study 808089 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric preparations of penicillin V (1 mill I.U.)
Number of subjects: 10
Study 808089 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (mixtures)
Number of subjects: 10
Study 808089 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (effervescent tablets, substance for drops and granulate)
Number of subjects: 10
Study 808089 — intervention group
Group type: EXPERIMENTAL
Intervention: All preparations
Number of subjects: 10
Study 30295912 — intervention group
Group type: EXPERIMENTAL
Intervention: Iyengar Yoga (twice-weekly for 8 weeks)
Number of subjects: 227
Study 30295912 — intervention group
Group type: COMPARATOR
Intervention: Wellness classes (control)
Number of subjects: 227
Study 28627125 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-week physical exercise intervention
Number of subjects: 0
Study 28627125 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (not specified as intervention or control)
Number of subjects: 0
Study 26862085 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaze-contingent attention training (120 min total, spread over six sessions)
Number of subjects: 27
Study 26862085 — intervention group
Group type: COMPARATOR
Intervention: Active control group
Number of subjects: 27
Study 26862085 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaze-contingent attention training
Number of subjects: 27
Study 25404436 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 60
Study 25404436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21918851 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI (including magnetic resonance angiography)
Number of subjects: 67
Study 19104366 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased access to emergency contraception (two free packs at enrollment with unlimited free resupply)
Number of subjects: 0
Study 19104366 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased access to emergency contraception
Number of subjects: 0
Study 19104366 — intervention group
Group type: COMPARATOR
Intervention: Standard access to emergency contraception
Number of subjects: 0
Study 17684704 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative 0.02% mitomycin-C (MMC) for 5 min
Number of subjects: 80
Study 17684704 — intervention group
Group type: COMPARATOR
Intervention: Limbal-conjunctival autograft (LCAG)
Number of subjects: 80
Study 15592925 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER tablet (10 mg) with menthol (100 mg initially, followed by 50 mg, 25 mg, and 25 mg at specified intervals)
Number of subjects: 11
Study 15592925 — intervention group
Group type: COMPARATOR
Intervention: Felodipine ER tablet (10 mg) with placebo
Number of subjects: 11
Study 14607627 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of AFPmRNA in HCC patients
Number of subjects: 126
Study 14607627 — intervention group
Group type: COMPARATOR
Intervention: Detection of AFPmRNA in control subjects
Number of subjects: 126
Study 14607627 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of AFPmRNA presence with metastasis
Number of subjects: 126
Study 10211846 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX) for 90 min at 58+/‐5% of maximal O2 uptake
Number of subjects: 8
Study 10211846 — intervention group
Group type: COMPARATOR
Intervention: Rest (RE) without exercise
Number of subjects: 8
Study 7616402 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal cocaethylene administration
Number of subjects: 8
Study 7616402 — intervention group
Group type: COMPARATOR
Intervention: Cocaine (as a comparator)
Number of subjects: 8
Study 7616402 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaethylene
Number of subjects: 8
Study 7616402 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaethylene and cocaine
Number of subjects: 8
Study 2619791 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 149
Study 2619791 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 149
Study 2619791 — intervention group
Group type: COMPARATOR
Intervention: No sedation
Number of subjects: 149
Study 1088916 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of methyldopa and hydrochlorothiazide
Number of subjects: 0
Study 1088916 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 0
Study 1088916 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study 31613178 — intervention group
Group type: EXPERIMENTAL
Intervention: guselkumab
Number of subjects: 1803
Study 31911261 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose prednisone (0.5 mg/kg/day for 6 months, max 30 mg daily) and methotrexate (15-20 mg once weekly for 6 months)
Number of subjects: 97
Study 31911261 — intervention group
Group type: COMPARATOR
Intervention: Standard dose prednisone (20 mg daily for 1 month, then 10 mg daily for 1 month, then 5 mg daily for one month then stop)
Number of subjects: 97
Study 29697354 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar cautery of lymphatic vessels
Number of subjects: 60
Study 29697354 — intervention group
Group type: COMPARATOR
Intervention: Suture ligature
Number of subjects: 60
Study 28505543 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple polyphenols (AP) 600mg/day for 12 weeks
Number of subjects: 65
Study 26383214 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV) at 10 cmH2O
Number of subjects: 50
Study 26383214 — intervention group
Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV) at 14 cmH2O
Number of subjects: 50
Study 22819549 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g of glucose
Number of subjects: 40
Study 22819549 — intervention group
Group type: COMPARATOR
Intervention: Tap water (control)
Number of subjects: 40
Study 21355146 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion at Zusanli (ST 36) and Sanyinjiao (SP 6)
Number of subjects: 97
Study 21355146 — intervention group
Group type: COMPARATOR
Intervention: Routine western medicine
Number of subjects: 97
Study 18579901 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-drop exercise (LD) group performing single-leg drop-landings from 14 cm, 3 sessions/week, 50 landings/session
Number of subjects: 42
Study 18579901 — intervention group
Group type: EXPERIMENTAL
Intervention: High-drop exercise (HD) group performing single-leg drop-landings from 28 cm, 3 sessions/week, 50 landings/session
Number of subjects: 42
Study 18579901 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined data from both exercise groups (LD and HD)
Number of subjects: 42
Study 18579901 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 42
Study 16441739 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-TCP+0.3 mg/ml of rhPDGF-BB
Number of subjects: 47
Study 16441739 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-TCP+1.0 mg/ml of rhPDGF-BB
Number of subjects: 47
Study 16441739 — intervention group
Group type: COMPARATOR
Intervention: beta-TCP osteoconductive scaffold alone (active control)
Number of subjects: 47
Study 12900807 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTF) 1,200 mg/d for 4 months
Number of subjects: 45
Study 12900807 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 healthy individuals)
Number of subjects: 45
Study 10871195 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model
Number of subjects: 0
Study 10871195 — intervention group
Group type: EXPERIMENTAL
Intervention: Deconvolution method
Number of subjects: 0
Study 10871195 — intervention group
Group type: COMPARATOR
Intervention: Simplified deconvolution method
Number of subjects: 0
Study 10871195 — intervention group
Group type: COMPARATOR
Intervention: C-peptide kinetics with somatostatin infusion
Number of subjects: 0
Study 10871195 — intervention group
Group type: COMPARATOR
Intervention: C-peptide kinetics without somatostatin infusion
Number of subjects: 0
Study 9093336 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led home management training programme (n = 96)
Number of subjects: 201
Study 9093336 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 105)
Number of subjects: 201
Study 8472735 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,000 IU unfractionated heparin
Number of subjects: 155
Study 8472735 — intervention group
Group type: COMPARATOR
Intervention: 5,000 IU unfractionated heparin + 0.5 mg dihydroergotamine mesylate twice daily
Number of subjects: 155
Study 3829464 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified cellulose (MC, 1.2 m2)
Number of subjects: 10
Study 3829464 — intervention group
Group type: COMPARATOR
Intervention: Regenerated cellulose (RC, 1.2 m2)
Number of subjects: 10
Study 3829464 — intervention group
Group type: COMPARATOR
Intervention: Cellulose acetate (CA, 1.0 m2)
Number of subjects: 10
Study 3829464 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified cellulose (MC)
Number of subjects: 10
Study 3829464 — intervention group
Group type: COMPARATOR
Intervention: Regenerated cellulose (RC)
Number of subjects: 10
Study 3829464 — intervention group
Group type: COMPARATOR
Intervention: Cellulose acetate (CA)
Number of subjects: 10
Study 29360661 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus letrozole
Number of subjects: 666
Study 29360661 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus letrozole
Number of subjects: 666
Study 26914104 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) administered over 12 weeks (24 sessions)
Number of subjects: 137
Study 26914104 — intervention group
Group type: COMPARATOR
Intervention: Oral pilocarpine (PC) 5 mg three times daily over 12 weeks
Number of subjects: 137
Study 25902100 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-oculogram recordings with mydriasis
Number of subjects: 55
Study 25902100 — intervention group
Group type: COMPARATOR
Intervention: Electro-oculogram recordings without mydriasis
Number of subjects: 55
Study 25902100 — intervention group
Group type: EXPERIMENTAL
Intervention: Age influence on Arden ratio, dark-trough, light-peak
Number of subjects: 55
Study 25902100 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of tested eyes
Number of subjects: 55
Study 23377066 — intervention group
Group type: EXPERIMENTAL
Intervention: Freehand method
Number of subjects: 54
Study 23377066 — intervention group
Group type: COMPARATOR
Intervention: Computer-aided methods
Number of subjects: 54
Study 20497149 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq
Number of subjects: 100
Study 20497149 — intervention group
Group type: COMPARATOR
Intervention: lightwand
Number of subjects: 100
Study 18504081 — intervention group
Group type: EXPERIMENTAL
Intervention: C804A polymorphism in the LTA gene
Number of subjects: 5804
Study 15897673 — intervention group
Group type: EXPERIMENTAL
Intervention: low dose (S)-ketamine
Number of subjects: 12
Study 15897673 — intervention group
Group type: EXPERIMENTAL
Intervention: high dose (S)-ketamine
Number of subjects: 12
Study 15897673 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 12617378 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal vibration using a percutaneous bladder stimulator (Queen Square Bladder Stimulator; Malem Medical)
Number of subjects: 28
Study 12617378 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal pressure
Number of subjects: 28
Study 12617378 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 28
Study 12617378 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between abdominal pressure and vibration
Number of subjects: 28
Study 10575269 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (300 mg o.d. for 3 days)
Number of subjects: 160
Study 10575269 — intervention group
Group type: COMPARATOR
Intervention: BCG (81 mg, 6 weekly instillations)
Number of subjects: 160
Study 10575269 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 160
Study 10575269 — intervention group
Group type: COMPARATOR
Intervention: BCG
Number of subjects: 160
Study 10575269 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid and BCG
Number of subjects: 160
Study 10575269 — intervention group
Group type: COMPARATOR
Intervention: Placebo and BCG
Number of subjects: 160
Study 8811474 — intervention group
Group type: EXPERIMENTAL
Intervention: GTR with self supporting membranes combined with the modified papilla preservation technique (group A)
Number of subjects: 45
Study 8811474 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional guided tissue regeneration (GTR) with non‐resorbable expanded polytetrafluoroethilene (ePTFE) membranes (group B)
Number of subjects: 45
Study 8811474 — intervention group
Group type: COMPARATOR
Intervention: Access flap (group C)
Number of subjects: 45
Study 1585760 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-contact therapy with 1% Micanol, average application time 13 minutes, increased to 2.5% and 185 minutes after six weeks
Number of subjects: 49
Study 1585760 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-contact therapy with 0.1% Micanol, average application time 8 hours, increased to 0.33% and 14 hours after six weeks
Number of subjects: 49
Study 3907742 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (tricyclic)
Number of subjects: 0
Study 3907742 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin (tetracyclic)
Number of subjects: 0
Study 3907742 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30735234 — intervention group
Group type: COMPARATOR
Intervention: LBS-only group (larger bonus size only)
Number of subjects: 8118
Study 30735234 — intervention group
Group type: COMPARATOR
Intervention: LBS plus ISP group (larger bonus size + increased social pressure)
Number of subjects: 8118
Study 30735234 — intervention group
Group type: COMPARATOR
Intervention: LBS plus LA group (larger bonus size + loss aversion)
Number of subjects: 8118
Study 29433442 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention
Number of subjects: 3845
Study 29433442 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic medications
Number of subjects: 3845
Study 29433442 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to specialist services
Number of subjects: 3845
Study 26908127 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel® (LAN) 120 mg every 4 weeks for 96 weeks
Number of subjects: 204
Study 26908127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 25728101 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy with nitrous oxide gas
Number of subjects: 30
Study 25728101 — intervention group
Group type: COMPARATOR
Intervention: Topical corticosteroids (triamcinolone acetonide 0.1% ointment in orabase)
Number of subjects: 30
Study 23095934 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc (MVC) + Combivir
Number of subjects: 876
Study 23095934 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV) + Combivir
Number of subjects: 876
Study 23095934 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc (MVC)
Number of subjects: 876
Study 23095934 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc (MVC) and Efavirenz (EFV)
Number of subjects: 876
Study 23095934 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype and ESTA screening
Number of subjects: 876
Study 19364444 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental intervention
Number of subjects: 288
Study 19364444 — intervention group
Group type: COMPARATOR
Intervention: Control (knowledge only) intervention
Number of subjects: 288
Study 18006208 — intervention group
Group type: EXPERIMENTAL
Intervention: L-theanine (250 mg)
Number of subjects: 0
Study 18006208 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (150 mg)
Number of subjects: 0
Study 18006208 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of L-theanine and caffeine
Number of subjects: 0
Study 18006208 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 16202779 — intervention group
Group type: EXPERIMENTAL
Intervention: Early diagnosis through newborn screening (NBS)
Number of subjects: 0
Study 16202779 — intervention group
Group type: COMPARATOR
Intervention: Control group (not screened)
Number of subjects: 0
Study 11978277 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist + daily norethindrone acetate 5 mg
Number of subjects: 123
Study 11978277 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist + daily norethindrone acetate 5 mg and conjugated equine estrogens 0.625 mg
Number of subjects: 123
Study 11978277 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist + daily norethindrone acetate 5 mg and conjugated equine estrogens 1.25 mg
Number of subjects: 123
Study 11978277 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist + daily placebo
Number of subjects: 123
Study 10590325 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV6b VLPs without adjuvant
Number of subjects: 32
Study 9348142 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulkforming agent (Volcolon: psyllium fibres)
Number of subjects: 269
Study 9348142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study 9348142 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin 6 mgr daily
Number of subjects: 269
Study 8444411 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha plus zidovudine
Number of subjects: 24
Study 8444411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8444411 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha
Number of subjects: 24
Study 2878461 — intervention group
Group type: EXPERIMENTAL
Intervention: lormetazepam (0.06 mg/kg) with Ro 15‐1788 (0.1 mg/kg)
Number of subjects: 18
Study 2878461 — intervention group
Group type: EXPERIMENTAL
Intervention: flunitrazepam (0.03 mg/kg) with Ro 15‐1788 (0.1 mg/kg)
Number of subjects: 18
Study 2878461 — intervention group
Group type: COMPARATOR
Intervention: placebo with Ro 15‐1788 (0.1 mg/kg)
Number of subjects: 18
Study 2878461 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 15‐1788 (0.1 mg/kg) 24 h after BZ treatment
Number of subjects: 18
Study 2878461 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural responses under BZ treatment
Number of subjects: 18
Study 29808433 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual CBT and workplace meeting (intervention)
Number of subjects: 137
Study 29808433 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 137
Study 26363806 — intervention group
Group type: COMPARATOR
Intervention: 0.25% bupivacaine
Number of subjects: 40
Study 26363806 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine
Number of subjects: 40
Study 24895285 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox
Number of subjects: 8
Study 24895285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 20561061 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Flask (TF)
Number of subjects: 30
Study 20561061 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Flask (DF)
Number of subjects: 30
Study 20561061 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Flask (HHF)
Number of subjects: 30
Study 20561061 — intervention group
Group type: COMPARATOR
Intervention: Control (TF) vs Experimental (HHF)
Number of subjects: 30
Study 20561061 — intervention group
Group type: COMPARATOR
Intervention: Control (TF) vs Experimental (DF)
Number of subjects: 30
Study 20561061 — intervention group
Group type: COMPARATOR
Intervention: Control (DF) vs Experimental (HHF)
Number of subjects: 30
Study 20488494 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis
Number of subjects: 203
Study 20488494 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic treatment
Number of subjects: 203
Study 20488494 — intervention group
Group type: COMPARATOR
Intervention: Surveillance only (Control)
Number of subjects: 203
Study 18411236 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichloroacetate
Number of subjects: 36
Study 15921807 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 2498
Study 15921807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2498
Study 12427851 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind individuals
Number of subjects: 19
Study 12427851 — intervention group
Group type: COMPARATOR
Intervention: Sighted individuals
Number of subjects: 19
Study 10477323 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg carbamazepine immediate release tablets in SLS (1% sodium lauryl sulfate in water)
Number of subjects: 4
Study 10477323 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg carbamazepine immediate release tablets in HC (0.1 mol/l Hydrochloric acid in water)
Number of subjects: 4
Study 10477323 — intervention group
Group type: EXPERIMENTAL
Intervention: Specification for dissolution testing in SLS
Number of subjects: 4
Study 10477323 — intervention group
Group type: COMPARATOR
Intervention: USP specification for dissolution testing
Number of subjects: 4
Study 8943962 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg daily
Number of subjects: 1145
Study 8943962 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily
Number of subjects: 1145